Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Licitra, L.
Right arrow Articles by Vermorken, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Licitra, L.
Right arrow Articles by Vermorken, J. B.
Related Collections
Right arrow 2004 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:7-11, 2004
© 2004 European Society for Medical Oncology

Is there still a role for neoadjuvant chemotherapy in head and neck cancer?

Received 10 February 2003; revised 3 June 2003; accepted 28 July 2003

After ~20 years of conflicting results from chemotherapy in randomized trials in advanced head and neck cancer, three meta-analyses reviewed its use. All three concluded that chemotherapy was associated with a statistically significant advantage in survival, but that this was low (4% absolute benefit at 2 and 5 years). The improvement in survival was mainly based on the more robust improvement obtained with the concomitant use of chemotherapy and radiotherapy. Induction chemotherapy, in particular, was not associated with any relevant survival advantage.

This article reviews current indications for neoadjuvant chemotherapy in advanced head and neck cancer. Implications for current and future research are discussed.

L. Licitra1,* and J. B. Vermorken2

1 Medical Oncology Unit, Head & Neck Department, Istituto Nazionale Tumori, Milan, Italy; 2 Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium

Key words: head and neck cancer, neoadjuvant chemotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
J.-L. Lefebvre
Current clinical outcomes demand new treatment options for SCCHN
Ann. Onc., January 1, 2005; 16(suppl_6): vi7 - vi12.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Bourhis
New approaches to enhance chemotherapy in SCCHN
Ann. Onc., January 1, 2005; 16(suppl_6): vi20 - vi24.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.